Halozyme: Roche’s OCREVUS SC with ENHANZE receives EC approval

Halozyme Therapeutics (HALO) announced that Roche (RHHBY) received European Commission marketing authorization of OCREVUS SC co-formulated with ENHANZE, Halozyme’s proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. OCREVUS SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic.